Halma has acquired two specialist healthcare businesses, Dutch digital health firm itemedical and Swedish oncology company Naslund Medical, in a pair of bolt-on deals worth a combined £54m.
The FTSE 100 safety and health technology group is paying €23m (£20m) for itemedical, which will sit within its SSG business, and $45m (£34m) for Naslund Medical, which joins IZI Medical. Both deals are on a cash- and debt-free basis and will be funded from Halma’s existing facilities.
itemedical provides digital platforms that integrate real-time patient data and alarms from various medical devices, helping hospital staff make faster clinical decisions and run wards more efficiently. Halma sees the business as a way to deepen SSG’s digital offering as hospitals accelerate their shift towards digitalised systems.
itemedical generated revenue of €7.8m in the 12 months to 31 March 2026.
Naslund Medical specialises in fiducial markers used in targeted cancer treatment. Its flagship Gold Anchor product allows clinicians to pinpoint tumours more precisely during radiation therapy, and will sit alongside IZI Medical’s existing Visicoil platform, giving customers a broader range of premium marker technologies. Naslund’s established international footprint also supports IZI’s plans to expand globally. The company posted revenue of $9.2m over the same 12-month period.
The acquisitions are typical of Halma’s long-standing strategy of buying niche businesses in markets with durable growth drivers, in this case, hospital digitalisation and precision oncology.
Marc Ronchetti, Group Chief Executive of Halma, said: “These acquisitions strengthen our existing companies by adding complementary capabilities in markets they know well, supporting their long-term growth while enabling improved patient outcomes. They operate in areas which have attractive long-term growth drivers and provide a strong platform for continued innovation and international expansion. We are pleased to welcome itemedical and Naslund Medical to Halma.”